Zealand's hypoglycemia candidate meets in first Phase III

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said dasiglucagon (ZP4207) met the primary endpoint in a Phase III trial to treat severe hypoglycemia in patients with Type I diabetes. The trial is evaluating a liquid formulation of dasiglucagon, a stable glucagon analog, in the ready-to-use HypoPal rescue pen.

The primary endpoint of the 90-patient trial evaluated the incidence of treatment-induced and treatment-boosted anti-drug antibodies (ADAs) following three repeat doses of subcutaneous 0.6 mg dasiglucagon or subcutaneous GlucaGen (native glucagon powder) from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Zealand said no treatment-induced or treatment-boosted ADAs were detected in the trial. Additional data are expected next quarter...